In accordance with previous literature, we found a shortened biological survival due to inefficacy or adverse events in RF-positive RA patients but also the inability to taper TNF inhibitors after reaching remission in ACPA-positive RA patients [22]. This evidence concerns the gene PRTN3 and rheumatoid arthritis.